• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2020

View Archived Issues

A stinging defeat for infections

Read More

Researchers develop a new murine model of seizures with Chd8 haploinsufficiency

Read More

DUSP6 is implicated in vascular disease and may be a therapeutic target

Read More

Abpro completes dosing in phase I trial of ABP-300 for COVID-19

Read More

Optimization of selective antagonists of vasopressin V1A receptor derived from triazolobenzazepines

Read More

Hyaluronan is present in the alveolar spaces in lungs of patients with fatal COVID-19

Read More

SARS-CoV-2 RNA genome can be targeted using small-molecule binders and RIBOTAC degraders

Read More

Phase III study of masitinib in severe asthma uncontrolled by ICS meets primary endpoint

Read More

Oxeia initiates phase II study of OXE-103 for concussions

Read More

Storm Therapeutics patents METTL3 inhibitors

Read More

Centauri Therapeutics divulges new antibacterials

Read More

Array BioPharma presents new PTPN11 inhibitors

Read More

First patient enrolled in MERKLIN 2 trial of domatinostat plus avelumab in MCC

Read More

New CDK inhibitors presented by Aurigene Discovery Technologies

Read More

Sorrento Therapeutics patents CD38-targeting antibodies

Read More

Poseida and TScan collaborate to develop TCR-T cell therapies for treatment of COVID-19

Read More

Second part of daratumumab CASSIOPEIA study in multiple myeloma meets primary endpoint

Read More

First-in-human injection of [68]Ga-NT-20.3 found to be well-tolerated without AEs

Read More

Phase I data presented for RP-L201 in patients with LAD-I

Read More

Gene therapy approaches tackle multiple forms of blindness

Read More

FDA clears Cyclo to open global phase III trial of Trappsol Cyclo for NPC in U.S.

Read More

MAb 5D3-mertansine antibody-drug conjugate shows efficacy in prostate cancer mouse models

Read More

Ultimovacs reports 5-year OS data from phase I trial of UV-1 in NSCLC

Read More

Nanoform targets initiation of first-in-human trial of nanoformed piroxicam before year-end

Read More

Daiichi initiates phase I trial of DS-1055 in advanced or metastatic solid tumors

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe